Please login to the form below
lymphoma
This page shows the latest lymphoma news and features for those working in and with pharma, biotech and healthcare.
Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia. ... FL is the most common slow-growing form of blood cancer non-Hodgkin lymphoma, which
Latest news
-
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Tecartus is used to treat adults with mantle cell lymphoma, and is indicated for patients whose cancer has returned after two or more previous treatments, including a BTK inhibitor. ... Meanwhile, Yescarta is used to treat follicular lymphoma and is also
-
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
Targets include the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK), c-ROS oncogene 1 (ROS1), and rearranged during transfection (RET), to name a few.
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
Gilead company Kite has unveiled positive results for its CAR-T therapy Yescarta in the second-line setting for relapsed or refractory large B-cell lymphoma (LBCL). . ... EFS was defined in the study as the time from randomisation to disease
-
CHMP recommends eight new medicines for EU approval
The CHMP also adopted a positive opinion for MorphoSys and Incyte’s Monjuvi (tafasitamab) for the treatment of relapsed or refractory diffuse B-cell lymphoma (DLBCL) for patients who are not
-
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
We are excited about the potential of Shoreline’s next-generation approach to allogeneic development, and how our collaboration can accelerate this research across different leukaemias and lymphomas,” he added.
More from news
Approximately 63 fully matching, plus 388 partially matching documents found.
Latest Intelligence
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Surviving cancer: a new era for patients
CAR-T therapy has potential across all tumour types, with recent results showing impressive overall response rates and complete response rates in patients with aggressive B-cell lymphomas.
-
Cortellis Drugs to Watch in 2020 report
11. Liso-cel for large B-cell lymphoma is being developed by Bristol-Myers Squibb to treat large B-cell lymphomas, and a filing in the third-line setting is being
-
Can protein degraders unlock ‘undruggable’ drug targets?
start initial human testing of its lead candidate KYM-001 in 2020 that is said to have potential in various cancers including a particularly aggressive subset of B-cell lymphoma. ... The company estimates that mutations in the MYD88 gene involved in that
-
Integrating patient reported outcomes into clinical trials
Takeda, for example, used EQ- 5D in its Adcetris programme despite doubts about whether the measure was sensitive enough to show the therapy’s effect on cutaneous T-cell lymphoma (CTCL)
More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.
Latest appointments
-
New hires at Abbott, Kite and Arrakis Therapeutics
Previously, he spent many years at Celgene, where he was corporate vice president for clinical R7D and the therapeutic area head for Lymphoma and CLL.
-
Kite Pharma appoints cancer immunotherapy experts
Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder
-
Charles Morris appointed chief development officer at ImmunoGen
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
-
Sutro Biopharma hires chief business officer and VP research
During his time at Allos, he set up a collaboration with Mundipharma for the co-development and commercialisation of lymphoma therapy Folotyn (pralatrexate) outside the US and Canada.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Highlights in haematologic malignancy from ASH 2018
refractory diffuse large B-cell lymphoma.
-
Australian Flu and the dilemma of naming diseases
s Lymphoma and Parkinsons.
-
Attracting doctors to low-demand specialties: A role for industry?
such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two sessions. .
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen’s Aduhelm unlikely to get approval in Europe
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- The pandemic preparedness paradox
- First trial of a vaccine against Alzheimer’s launches
- Good NICE news for Pfizer, but Dendreon drug rejected
PMHub
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
